Solution Providers
Solution Providers

newswirelogo

  • NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. Company developing treatments for rare and life-threatening diseases, today announced it has confidentially submitted a draft registration statement on Form S-1 to the Securities and Exchange Commission (the “SEC”) related to its proposed initial public offering. The number of shares of stock and the price range for the proposed offering have not yet been determined. The proposed offering is subject to, among other things, completion of SEC review process and market conditions.

  • 采用新一代柴油技术
    快速获取清洁空气效益

  • Adoção de tecnologia diesel de última geração 
    oferece rápidos benefícios para um ar mais limpo 

    Novo conhecimento sobre a qualidade do ar global destaca a necessidade por tecnologias como motores a diesel de última geração que são capazes de acelerar a redução das emissões

  • Adopción de la nueva generación de tecnología diésel 
    Proporciona rápidos beneficios de aire limpio
     

    La nueva comprensión de la calidad del aire a nivel mundial destaca la necesidad de tecnologías como los motores diésel de nueva generación, que son capaces de acelerar la reducción de las emisiones.

  • Adopsi Teknologi Diesel Generasi Baru
    Memberikan Manfaat Udara Bersih secara Cepat

    Pemahaman baru tentang kualitas udara global menyoroti kebutuhan akan teknologi seperti mesin diesel generasi baru, yang mampu mempercepat pengurangan emisi .

Contact Us

Retail Merchandiser Magazine
150 N. Michigan Ave., Suite 900
Chicago, IL 60601

  312.676.1100
  312.676.1101

Click here for a full list of contacts.

Latest Edition

Spread The Love

Back To Top